The FDA's decision to phase out phenylephrine, the leading decongestant in over-the-counter medications, is based on evidence suggesting it does not actually relieve nasal congestion.
Federal advisers unanimously concluded that oral phenylephrine medications provide no better relief from congestion than a placebo, prompting the FDA to propose revoking its usage.
Experts found the studies from the 1960s and 70s that supported phenylephrine's initial use were flawed, highlighting growing skepticism toward this long-used decongestant.
Dr. Brian Schroer emphasizes that removing ineffective products like phenylephrine allows consumers to more easily select effective treatments for their cold and flu symptoms.
Collection
[
|
...
]